NO20041941L - Doseringsform, utstyr og fremgangsmater for behandling - Google Patents

Doseringsform, utstyr og fremgangsmater for behandling

Info

Publication number: NO20041941L
Authority: NO; Norway
Prior art keywords: formulation; active agent; rumen; amounts; predetermined
Prior art date: 2001-10-19

Application number

NO20041941A

Other languages

English (en)

Norwegian (no)

Inventor

Lionel Barry Lowe

Joseph Raymond Winkle

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-19

Filing date

2004-05-10

Publication date

2004-05-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3832213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20041941(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-05-10 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2004-05-10 Publication of NO20041941L publication Critical patent/NO20041941L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0068—Rumen, e.g. rumen bolus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Tropical Medicine & Parasitology (AREA)
Physiology (AREA)
Inorganic Chemistry (AREA)
Nutrition Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20041941A 2001-10-19 2004-05-10 Doseringsform, utstyr og fremgangsmater for behandling NO20041941L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AUPR8390A AUPR839001A0 (en)	2001-10-19	2001-10-19	Dosage form, device and methods of treatment
PCT/AU2002/001426 WO2003033031A1 (fr)	2001-10-19	2002-10-18	Forme posologique, dispositif et procedes de traitement

Publications (1)

Publication Number	Publication Date
NO20041941L true NO20041941L (no)	2004-05-10

Family

ID=3832213

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20041941A NO20041941L (no)	2001-10-19	2004-05-10	Doseringsform, utstyr og fremgangsmater for behandling

Country Status (22)

Country	Link
US (1)	US20050064032A1 (fr)
EP (1)	EP1448151A4 (fr)
JP (1)	JP2005510485A (fr)
KR (1)	KR20050037410A (fr)
CN (1)	CN1571663A (fr)
AR (1)	AR037116A1 (fr)
AU (5)	AUPR839001A0 (fr)
BR (1)	BR0212975A (fr)
CA (1)	CA2463674A1 (fr)
CR (1)	CR7312A (fr)
EA (1)	EA005778B1 (fr)
EC (1)	ECSP045063A (fr)
HR (1)	HRP20040231A2 (fr)
HU (1)	HUP0401808A3 (fr)
IL (1)	IL160754A0 (fr)
MX (1)	MXPA04003679A (fr)
NO (1)	NO20041941L (fr)
NZ (1)	NZ531672A (fr)
PE (1)	PE20030519A1 (fr)
PL (1)	PL368387A1 (fr)
WO (1)	WO2003033031A1 (fr)
ZA (1)	ZA200403743B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITRN20030021A1 (it) *	2003-07-21	2005-01-22	Ascor Chimici Srl	Composizione di materia comprendente particelle contenenti cloruro di colina da somministrare in forma ruminalmente protetta e post-ruminalmente efficace.
ITMI20041820A1 (it) *	2004-09-24	2004-12-24	Ascor Chimici Srl	Composizione in micro-pellets a rilascio controllato di sostanze fisiologicamente attive, procedimento di preparazione e relativo impiego nel settore zootecnico.
KR100866720B1 (ko) *	2004-12-27	2008-11-05	에자이 알앤드디 매니지먼트 가부시키가이샤	항치매 약물의 안정화 방법
US20090208579A1 (en) *	2004-12-27	2009-08-20	Eisai R & D Management Co., Ltd.	Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060280789A1 (en) *	2004-12-27	2006-12-14	Eisai Research Institute	Sustained release formulations
US20060246003A1 (en) *	2004-12-27	2006-11-02	Eisai Co. Ltd.	Composition containing anti-dementia drug
NZ554260A (en) *	2007-09-30	2010-05-28	Agres Ltd	Selenomethionine andor selenocysteine administration to non-human animals to increase selenium content in protein sources
WO2010126857A1 (fr) *	2009-04-28	2010-11-04	Wyeth Llc	Combinaisons antiparasitaires de lactones macrocycliques et d'antibiotiques polyéther
US8734430B2 (en)	2009-07-31	2014-05-27	Merial Limited	Sustained release capsules
AU2014203209B2 (en) *	2009-07-31	2015-11-26	Boehringer Ingelheim Animal Health USA Inc.	Sustained release capsules
WO2011075592A1 (fr) *	2009-12-17	2011-06-23	Merial Limited	Compositions contenant des composés de lactone macrocyclique et des spiro-dioxépino-indoles
FR2992219B1 (fr) *	2012-06-22	2014-07-11	Aditec Lab	Composition pour le traitement de l'hypocalcemie chez les ruminants
DK3164117T3 (da)	2014-07-03	2023-12-04	SpecGx LLC	Misbrugssikre formuleringer med øjeblikkelig frigivelse omfattende ikke-cellulose-polysaccharider
AU2017216904B2 (en)	2016-02-08	2021-11-18	SpecGx LLC	Glucomannan containing pharmaceutical compositions with extended release and abuse deterrent properties
IL266377B2 (en) *	2016-12-02	2023-10-01	Clexio Biosciences Ltd	Gastric residence system
NZ760663A (en) *	2017-06-26	2025-11-28	Boehringer Ingelheim Animal Health Usa Inc	Dual active parasiticidal granule compositions, methods and uses thereof
USD909604S1 (en)	2017-08-25	2021-02-02	Argenta Manufacturing Limited	Barrel of an intraruminal device
AU2019338076B2 (en) *	2018-09-10	2025-07-31	Argenta Innovation Limited	Controlled release formulations in delivery devices
BR112021004523A2 (pt) *	2018-09-10	2021-06-08	Argenta Innovation Limited	formulações para liberação sustentada em dispositivos de administração
CA3112030A1 (fr)	2018-09-25	2020-04-02	SpecGx LLC	Formes posologiques de capsules a liberation immediate anti-abus
PL4013348T3 (pl) *	2019-08-14	2024-07-08	Elanco Tiergesundheit Ag	Nowy ochraniacz skrzydełek do oskrzydlonej kapsułki i sposób jego stosowania
BR112022014865A2 (pt) *	2020-02-07	2022-09-20	Elanco Animal Health Incorporated	Cápsula alada
WO2021242481A1 (fr) *	2020-05-28	2021-12-02	Boehringer Ingelheim Animal Health USA Inc.	Dispositif de capsule intraruminale à libération bimodale et ses méthodes d'utilisation
CA3201057A1 (fr)	2020-12-08	2022-06-16	Mark Christopher LAY	Ameliorations apportees a des dispositifs et des methodes d'administration de substances aux animaux
CN113398337A (zh) *	2021-06-23	2021-09-17	上海市肺科医院	包含抗结核药物缓释植入人工骨载体的脊柱内固定装置
CN118743817B (zh) *	2024-09-04	2025-01-21	中国农业大学	一种瘤胃持续给药系统
CN119454625A (zh) *	2024-10-29	2025-02-18	山东鲁西兽药股份有限公司	一种反刍动物用驱虫中药提取物微量元素维生素缓释丸

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU520409B2 (en) *	1977-05-25	1982-01-28	Commonwealth Scientific And Industrial Research Organisation	Controlled release composition
GB2077586A (en) *	1980-06-12	1981-12-23	Standard Telephones Cables Ltd	Sustained-release device
NZ197543A (en) *	1980-07-02	1984-12-14	Commw Scient Ind Res Org	Controlled release compositions for inclusion in intraruminal devices
US4416659A (en) *	1981-11-09	1983-11-22	Eli Lilly And Company	Sustained release capsule for ruminants
NZ203203A (en) *	1982-02-16	1985-09-13	Commw Scient Ind Res Org	Controlled release device:gas diffusion limited
IE54171B1 (en) *	1982-06-22	1989-07-05	Univ Glasgow	Device for introducing nutrients and/or therapeutic materials into ruminant animals
GB8328916D0 (en) *	1983-10-28	1983-11-30	Castex Prod	Pharmaceutical pellet
US4777049A (en) *	1983-12-01	1988-10-11	Alza Corporation	Constant release system with pulsed release
NZ212100A (en) *	1984-06-02	1988-07-28	Castex Prod	Rumen bolus; outer casing sheds in segments
US4723958A (en) *	1986-05-23	1988-02-09	Merck & Co., Inc.	Pulsatile drug delivery system
US4867980A (en) *	1986-10-10	1989-09-19	Coopers Animal Health Australia Limited	Heavy density depot
US5938654A (en) *	1987-06-25	1999-08-17	Alza Corporation	Osmotic device for delayed delivery of agent
US5023088A (en) *	1987-06-25	1991-06-11	Alza Corporation	Multi-unit delivery system
US5391381A (en) *	1987-06-25	1995-02-21	Alza Corporation	Dispenser capable of delivering plurality of drug units
US4957494A (en) *	1987-06-25	1990-09-18	Alza Corporation	Multi-layer delivery system
US4874388A (en) *	1987-06-25	1989-10-17	Alza Corporation	Multi-layer delivery system
US5110597A (en) *	1987-06-25	1992-05-05	Alza Corporation	Multi-unit delivery system
US4915949A (en) *	1987-07-13	1990-04-10	Alza Corporation	Dispenser with movable matrix comprising a plurality of tiny pills
GB8829089D0 (en) *	1988-12-13	1989-01-25	Coopers Animal Health	Intra ruminal device
EP0386440B1 (fr) *	1989-02-11	1992-08-05	Bayer Ag	Médicament à libération contrôlée
US5110598A (en) *	1989-06-30	1992-05-05	Smithkline Beecham Corp.	Intermittent release dosage form
US5126142A (en) *	1989-07-18	1992-06-30	Alza Corporation	Dispenser comprising ionophore
US5017381A (en) *	1990-05-02	1991-05-21	Alza Corporation	Multi-unit pulsatile delivery system
MX9200339A (es) *	1991-01-28	1992-08-01	Hoechst Ag	Preparado para la liberacion controlada de sustancias activas, que son apropiadas como terapeuticos o para mejorar el crecimiento y el aprovechamiento de los piensos en rumiantes
US5417682A (en) *	1991-01-30	1995-05-23	Alza Corporation	Device for administering active agent to biological environment
AU650113B2 (en) *	1991-04-05	1994-06-09	Eli Lilly And Company	Sustained release capsule and formulations
US5240713A (en) *	1991-09-27	1993-08-31	Alza Corporation	Dual rate agent delivery device
US5221278A (en) *	1992-03-12	1993-06-22	Alza Corporation	Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
DE69531773T2 (de) *	1994-01-20	2004-07-15	Agresearch Ltd.	Vorrichtung zur verabreichung von nützlichen stoffen an wiederkäuer
AUPM897594A0 (en) *	1994-10-25	1994-11-17	Daratech Pty Ltd	Controlled release container
HU230454B1 (hu) *	1998-11-02	2016-07-28	Alkermes Pharma Ireland Limited	Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény
US6569857B1 (en) *	1999-05-03	2003-05-27	Drugtech Corporation	Dietary supplement
DE19956486A1 (de) *	1999-11-24	2001-06-21	Lohmann Therapie Syst Lts	Mehrschichtige Zubereitung zur gesteuerten, pulsartigen Abgabe von Wirkstoffen
CA2395892C (fr) *	1999-12-31	2014-06-03	Rutgers, The State University	Formulation pharmaceutique composee d'un melange polymere et d'un compose actif pour une liberation regulee dans le temps
AU2001237424A1 (en) *	2000-02-28	2001-09-12	Akzo Nobel N.V.	Bodies for the controlled release of active substances

2001
- 2001-10-19 AU AUPR8390A patent/AUPR839001A0/en not_active Abandoned
2002
- 2002-10-17 PE PE2002001028A patent/PE20030519A1/es not_active Application Discontinuation
- 2002-10-18 BR BR0212975-2A patent/BR0212975A/pt not_active IP Right Cessation
- 2002-10-18 CN CNA028207009A patent/CN1571663A/zh active Pending
- 2002-10-18 IL IL16075402A patent/IL160754A0/xx unknown
- 2002-10-18 AU AU2002332975A patent/AU2002332975C1/en not_active Expired
- 2002-10-18 EA EA200400557A patent/EA005778B1/ru not_active IP Right Cessation
- 2002-10-18 PL PL02368387A patent/PL368387A1/xx not_active Application Discontinuation
- 2002-10-18 EP EP02801251A patent/EP1448151A4/fr not_active Withdrawn
- 2002-10-18 WO PCT/AU2002/001426 patent/WO2003033031A1/fr not_active Ceased
- 2002-10-18 HR HR20040231A patent/HRP20040231A2/hr not_active Application Discontinuation
- 2002-10-18 NZ NZ531672A patent/NZ531672A/en not_active IP Right Cessation
- 2002-10-18 US US10/490,975 patent/US20050064032A1/en not_active Abandoned
- 2002-10-18 AR ARP020103936A patent/AR037116A1/es unknown
- 2002-10-18 HU HU0401808A patent/HUP0401808A3/hu unknown
- 2002-10-18 KR KR1020047005590A patent/KR20050037410A/ko not_active Ceased
- 2002-10-18 CA CA002463674A patent/CA2463674A1/fr not_active Abandoned
- 2002-10-18 MX MXPA04003679A patent/MXPA04003679A/es active IP Right Grant
- 2002-10-18 JP JP2003535833A patent/JP2005510485A/ja active Pending
2004
- 2004-04-15 EC EC2004005063A patent/ECSP045063A/es unknown
- 2004-04-16 CR CR7312A patent/CR7312A/es unknown
- 2004-05-10 NO NO20041941A patent/NO20041941L/no not_active Application Discontinuation
- 2004-05-14 ZA ZA200403743A patent/ZA200403743B/en unknown
- 2004-09-09 AU AU2004210542A patent/AU2004210542C1/en not_active Expired
2005
- 2005-10-28 AU AU2005227413A patent/AU2005227413A1/en not_active Abandoned
2009
- 2009-12-16 AU AU2009250987A patent/AU2009250987A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2002332975C1 (en)	2009-01-29
AUPR839001A0 (en)	2001-11-15
EA005778B1 (ru)	2005-06-30
MXPA04003679A (es)	2004-07-23
AU2004210542C1 (en)	2009-01-08
NZ531672A (en)	2006-08-31
ZA200403743B (en)	2005-05-16
AU2005227413A1 (en)	2005-11-17
KR20050037410A (ko)	2005-04-21
EP1448151A1 (fr)	2004-08-25
WO2003033031A1 (fr)	2003-04-24
BR0212975A (pt)	2004-10-13
EA200400557A1 (ru)	2005-02-24
HUP0401808A3 (en)	2005-11-28
AR037116A1 (es)	2004-10-20
HRP20040231A2 (en)	2004-08-31
ECSP045063A (es)	2004-05-28
AU2004210542B9 (en)	2005-09-01
CN1571663A (zh)	2005-01-26
IL160754A0 (en)	2004-08-31
CR7312A (es)	2004-10-27
EP1448151A4 (fr)	2010-01-13
AU2004210542A1 (en)	2004-09-30
PE20030519A1 (es)	2003-06-13
AU2002332975B9 (en)	2005-03-17
US20050064032A1 (en)	2005-03-24
PL368387A1 (en)	2005-03-21
AU2004210542B2 (en)	2005-07-28
AU2002332975B2 (en)	2005-02-03
AU2009250987A1 (en)	2010-01-14
CA2463674A1 (fr)	2003-04-24
HUP0401808A2 (hu)	2005-01-28
JP2005510485A (ja)	2005-04-21

Publication	Publication Date	Title
NO20041941L (no)	2004-05-10	Doseringsform, utstyr og fremgangsmater for behandling
Roehrborn et al.	2003	Safety and efficacy of alfuzosin 10 mg once‐daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double‐blind, placebo‐controlled studies
Gene et al.	2003	Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta‐analysis
Yemisci et al.	2005	Effects and side‐effects of spironolactone therapy in women with acne
AR038157A1 (es)	2004-12-29	Formas de dosificacion de benzimidazoles sustituidos y su uso
BR0114799A (pt)	2003-12-30	Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
EP1202725A4 (fr)	2004-02-04	Methode de traitement de symptomes de variations hormonales, y compris des bouffees de chaleur
Saracho et al.	1998	Evaluation of the losartan in hemodialysis (ELHE) study
Penston et al.	1989	Efficacy and safety of long-term maintenance therapy of duodenal ulcers
Malfertheiner et al.	2003	What constitutes failure for Helicobacter pylori eradication therapy?
Yamada et al.	2002	Influence of GnRH analogue (fertirelin acetate) doses on synchronization of ovulation and fixed-time artificial insemination in lactating dairy cows
Murakami et al.	2014	Tu1056 a phase 3, double-blind study of a triple therapy with TAK-438, amoxicillin, and clarithromycin as first line eradication of H. pylori and a triple therapy with TAK-438, amoxicillin, and metronidazole as second Line eradication of H. pylori
Gravis	1980	Ultrastructural observations on spermatozoa retained within the seminiferous epithelium after treatment with dibutyryl cyclic AMP
Van Rensburg et al.	2001	No clinical benefit of adding cisapride to pantoprazole for treatment of gastro-oesophageal reflux disease
Lahaie et al.	2001	Bismuth‐based quadruple therapy with bismuth subcitrate, metronidazole, tetracycline and omeprazole in the eradication of Helicobacter pylori
Uygun et al.	1999	Efficacy of omeprazole plus two antimicrobials for the eradication of Helicobacter pylori in a Turkish population
MY122477A (en)	2006-04-29	Sertraline oral concentrate
Olivennes	2006	The use of gonadotropin-releasing hormone antagonist in ovarian stimulation
Caixeta et al.	2012	Contrast‐induced nephropathy: Protective role of fenoldopam
AR037543A1 (es)	2004-11-17	Metodo para la terapia del cancer y composicion farmaceutica
Motta et al.	2018	A novel and safe strategy for resynchronization using estradiol 14 days after timed-AI in beef heifers
Müller et al.	2009	A novel herbal preparation desensitizes mesenteric afferents to bradykinin in the rat small intestine
Kwan et al.	1998	Attenuation of experimental subarachnoid hemorrhage-induced cerebral vasospasm by CGS 26303, an endothelin-converting enzyme inhibitor
Kovacs et al.	1999	Double‐blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2‐receptor antagonists
de Jesus Perez	2013	Understanding the pharmacokinetics of oral treprostinil in patients with pulmonary arterial hypertension

Legal Events

Date	Code	Title	Description
2010-05-31	FC2A	Withdrawal, rejection or dismissal of laid open patent application